Bosh sahifaMLLCF • OTCMKTS
add
Molecular Partners AG
Yopilish kursi
4,22 $
Yillik diapazon
3,66 $ - 6,70 $
Bozor kapitalizatsiyasi
174,00 mln USD
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
SWX
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CHF) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 0,00 | -100,00% |
Joriy xarajat | 5,34 mln | -7,37% |
Sof foyda | -11,23 mln | 43,22% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,30 | — |
EBITDA | -14,55 mln | 11,39% |
Amaldagi soliq stavkasi | -0,02% | — |
Balans
Jami aktivlari
Jami passivlari
| (CHF) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 149,44 mln | -20,04% |
Jami aktivlari | 158,53 mln | -20,08% |
Jami passivlari | 16,89 mln | -22,95% |
Umumiy kapital | 141,64 mln | — |
Tarqatilgan aksiyalar | 36,86 mln | — |
Narxi/balansdagi bahosi | 1,10 | — |
Aktivlardan daromad | -23,65% | — |
Kapitaldan daromad | -25,90% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CHF) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -11,23 mln | 43,22% |
Operatsiyalardan naqd pul | -13,20 mln | 17,47% |
Sarmoyadan naqd pul | -4,49 mln | -123,10% |
Moliyadan naqd pul | 15,30 mln | 5 234,56% |
Naqd pulning sof oʻzgarishi | -1,88 mln | -72,29% |
Boʻsh pul | -6,34 mln | 32,28% |
Haqida
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Tashkil etilgan
2004
Xodimlar soni
159
